# Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

Clinical trial · Hunan Province Tumor Hospital

- Archive id: nct:NCT04322617
- Published: 2020-03-26
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04322617
- Source URL: https://clinicaltrials.gov/study/NCT04322617
- Provenance: clinicaltrials

## Abstract

This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: ATHENA
- status: RECRUITING
- phase: PHASE2, PHASE3
- study type: INTERVENTIONAL
- enrollment: 1200
- sponsor: Hunan Province Tumor Hospital
- conditions: Non-small Cell Lung Cancer
- interventions: DRUG: Anlotinib plus the same Immune Checkpoint Inhibitors.; DRUG: Anlotinib plus the new Immune Checkpoint Inhibitors.; DRUG: Anlotinib
- start date: 2020-03-24
- start date type: ACTUAL
- primary completion date: 2028-03-24
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.